GlassScriptPhysician profile
Nelson E Uzquiano
NPI 1316010820
$996.11
in general payments reported to CMS, 2019-2025
14 companies · $58.79 in 2025
The $58.79 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $121 · 2021: $124 · 2022: $85.18 · 2023: $269 · 2024: $173 · 2025: $58.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.46 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.14 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $177.58 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $106.16 | 2022-2025 | |
| Exeltis, USA INC. | $98.09 | 2019-2021 | |
| Avion Pharmaceuticals | $94.60 | 2020-2023 | Balcoltra |
| Organon LLC | $53.68 | 2022-2024 | |
| Pfizer INC. | $46.60 | 2021-2022 | |
| Baxter Healthcare | $41.38 | 2024 | Tisseel |
| Myovant Sciences INC. | $33.55 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $27.55 | 2023 | Vivjoa |
| Mission Pharmacal Company | $23.16 | 2023 | Citranatal |
| Millicent US INC | $21.21 | 2024 | Femring, Intrarosa |
| Scynexis, INC. | $17.05 | 2022 | |
| Shield Therapeutics INC | $13.36 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Uzquiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.